TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+6.47%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.7B
AUM Growth
+$2.7B
(+4.7%)
Cap. Flow
-$19.8M
Cap. Flow
% of AUM
-0.73%
Top 10 Holdings %
Top 10 Hldgs %
44.18%
Holding
152
New
13
Increased
22
Reduced
28
Closed
8
Top Buys
| 1 |
Merck
MRK
|
$17.6M |
| 2 |
NVRO
NEVRO CORP.
NVRO
|
$14.5M |
| 3 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$14.1M |
| 4 |
Novartis
NVS
|
$12.5M |
| 5 |
Biogen
BIIB
|
$12.2M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$30.3M |
| 2 |
Molina Healthcare
MOH
|
$18.4M |
| 3 |
Thermo Fisher Scientific
TMO
|
$15.5M |
| 4 |
Pfizer
PFE
|
$11.3M |
| 5 |
Health Care Select Sector SPDR Fund
XLV
|
$10.5M |
Sector Composition
| 1 | Healthcare | 91.69% |
| 2 | Real Estate | 3.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Ventas
VTR
$30.7B
| $12.2M | 0.45% |
175,991
| – | – |
|
|
SGEN
52
DELISTED
Seagen Inc. Common Stock
SGEN
| $11.6M | 0.43% |
+223,700
| New | +$11.6M |
|
53
Acadia Healthcare
ACHC
$2.15B
| $11.4M | 0.42% |
231,200
| – | – |
|
|
DERM
54
DELISTED
Dermira, Inc.
DERM
| $11.3M | 0.42% |
386,900
+221,700
| +134% | +$6.46M |
|
|
AKRX
55
DELISTED
Akorn, Inc.
AKRX
| $11M | 0.41% |
327,735
| – | – |
|
|
DOC
56
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $10.7M | 0.4% |
530,672
| – | – |
|
57
Bristol-Myers Squibb
BMY
$96.7B
| $10.4M | 0.39% |
186,500
| – | – |
|
|
ENDP
58
DELISTED
Endo International plc
ENDP
| $10.2M | 0.38% |
914,548
| – | – |
|
59
Novo Nordisk
NVO
$252B
| $9.32M | 0.35% |
217,300
+134,300
| +162% | +$5.76M |
|
60
Alnylam Pharmaceuticals
ALNY
$58.6B
| $9.17M | 0.34% |
114,966
-129,029
| -53% | -$10.3M |
|
61
Sanofi
SNY
$122B
| $8.62M | 0.32% |
179,900
-125,100
| -41% | -$5.99M |
|
62
HCA Healthcare
HCA
$95.4B
| $8.3M | 0.31% |
95,232
+31,800
| +50% | +$2.77M |
|
63
CytomX Therapeutics
CTMX
$350M
| $8.22M | 0.3% |
530,092
| – | – |
|
|
CLLS
64
Cellectis
CLLS
$260M
| $8.01M | 0.3% |
310,250
| – | – |
|
65
Ultragenyx Pharmaceutical
RARE
$3.04B
| $7.91M | 0.29% |
127,308
+38,908
| +44% | +$2.42M |
|
|
PRAH
66
DELISTED
PRA Health Sciences, Inc.
PRAH
| $7.65M | 0.28% |
102,000
| – | – |
|
67
Merus
MRUS
$5.04B
| $7.6M | 0.28% |
479,150
| – | – |
|
68
Bausch Health
BHC
$2.72B
| $7.44M | 0.28% |
430,000
+238,000
| +124% | +$4.12M |
|
|
RARX
69
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $7.42M | 0.27% |
+395,818
| New | +$7.42M |
|
|
SAGE
70
DELISTED
Sage Therapeutics
SAGE
| $7.21M | 0.27% |
90,480
| – | – |
|
|
TTPH
71
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $7.16M | 0.27% |
1,004,322
| – | – |
|
|
LTC
72
LTC Properties
LTC
$1.67B
| $7M | 0.26% |
136,212
| – | – |
|
|
AVDL
73
Avadel Pharmaceuticals
AVDL
$1.42B
| $6.89M | 0.26% |
624,288
| – | – |
|
74
Karyopharm Therapeutics
KPTI
$61.4M
| $6.85M | 0.25% |
756,679
+151,455
| +25% | +$1.37M |
|
|
DPLO
75
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $6.83M | 0.25% |
461,712
+331,489
| +255% | +$4.91M |
|